# Vikeer (Weikaier)
Vikeer (江苏威凯尔, now formally 江苏威凯尔医药科技股份有限公司, Jiangsu Vikeer Pharmaceutical Co., Ltd.) is a Chinese chemical-drug company founded in 2010 in Nanjing that pairs one-stop CRO/CDMO services for small-molecule drugs with a pipeline of self-developed innovative medicines, and it remains active as of 2026.[1](https://bydrug.pharmcube.com/news/detail/6c2be0414dcbf8d92dd718ca0fd1754d) • [3](https://www.vcarepharmatech.com/news_detail/29.html) The company was created by China Pharmaceutical University professors and returned overseas scholars, and in 2025 it reached the commercial stage when its first internally discovered class-1 innovative drug won NMPA approval.[1](https://bydrug.pharmcube.com/news/detail/6c2be0414dcbf8d92dd718ca0fd1754d) • [3](https://www.vcarepharmatech.com/news_detail/29.html)
| Key fact | Detail |
|---|---|
| Founded | August 2010, Nanjing (Jiangbei New Area Biomedicine Valley), by China Pharmaceutical University professors and returnee scholars[1](https://bydrug.pharmcube.com/news/detail/6c2be0414dcbf8d92dd718ca0fd1754d) • [5](https://m.qcc.com/firm/1ec634273b2cf7a4ff4345833a2547be.html) |
| Business | Full-chain CRO/CDMO services for chemical drugs plus in-house innovative-drug R&D[1](https://bydrug.pharmcube.com/news/detail/6c2be0414dcbf8d92dd718ca0fd1754d) |
| Chairman | 龚彦春 (Gong Yanchun), per the company registry[5](https://m.qcc.com/firm/1ec634273b2cf7a4ff4345833a2547be.html) |
| Series A | Nearly USD 60 million (RMB 388 million) closed April 2022, with 国投招商 reinvesting and 长江产投 joining[1](https://bydrug.pharmcube.com/news/detail/6c2be0414dcbf8d92dd718ca0fd1754d) |
| Cumulative funding | Over RMB 1.2 billion in the five years to 2025 (company claim)[3](https://www.vcarepharmatech.com/news_detail/29.html) |
| First approved drug | 维迈妥® (Eratrectinib, VC004) for NTRK fusion solid tumors, NMPA-approved June 2025[3](https://www.vcarepharmatech.com/news_detail/29.html) |
| Status | Active (存续) per the company registry as of June 2026[5](https://m.qcc.com/firm/1ec634273b2cf7a4ff4345833a2547be.html) |
## History and founding
The company was founded in 2010 by professors from China Pharmaceutical University together with scholars who had returned from overseas.[1](https://bydrug.pharmcube.com/news/detail/6c2be0414dcbf8d92dd718ca0fd1754d) The registry entry records incorporation on 31 August 2010 with chairman Gong Yanchun.[5](https://m.qcc.com/firm/1ec634273b2cf7a4ff4345833a2547be.html)
By the time of its 2022 financing the company employed more than 400 people, over 83% of them technical staff, with 12 PhDs and more than 100 master's degree holders (a later report gave 13 PhDs and 110+ masters; the two accounts differ slightly and neither is confirmed).[1](https://bydrug.pharmcube.com/news/detail/6c2be0414dcbf8d92dd718ca0fd1754d) • [2](https://news.qq.com/rain/a/20220519A0846300) It had self-built a 21,000-square-meter drug R&D center on a 20-mu (about 1.3-hectare) site at a cost of RMB 200 million, located in the Jiangbei New Area biomedicine valley.[1](https://bydrug.pharmcube.com/news/detail/6c2be0414dcbf8d92dd718ca0fd1754d)
In November 2021 Vikeer established the wholly owned subsidiary 南京威凯尔生物医药科技有限公司 (Nanjing Vikeer Biopharmaceutical Technology) to run its one-stop, full-chain CRO/CDMO business independently, with a Phase II CDMO technology center under construction and a production base in Hubei.[1](https://bydrug.pharmcube.com/news/detail/6c2be0414dcbf8d92dd718ca0fd1754d)
## Products, technology and services
Vikeer operates a dual model. One side is contract services: the Nanjing subsidiary offers full-chain CRO/CDMO work for chemical drugs, meaning it can carry a client molecule from process development and analytical work through to manufacturing, supported by the Hubei production base.[1](https://bydrug.pharmcube.com/news/detail/6c2be0414dcbf8d92dd718ca0fd1754d) The other side is its own drug pipeline. As of May 2022 this comprised nine internal innovative-drug programs, three of them in Phase I to III clinical trials: the antithrombotic vicagrel (维卡格雷, P2Y12 target, China Phase III / US Phase I), the NTRK-targeted anticancer drug VC004 (China Ib), and the JAK1 inhibitor VC005 for autoimmune inflammation (China Phase I).[1](https://bydrug.pharmcube.com/news/detail/6c2be0414dcbf8d92dd718ca0fd1754d) • [2](https://news.qq.com/rain/a/20220519A0846300)
## Funding, by the numbers
In April 2022 Vikeer completed an A2 round in which 国投招商 (SDIC [Investment](https://www.edgepedia.org/investment), a state-backed investor) reinvested and 长江产投 (Yangtze River Industrial Investment) joined, closing the Series A at a total of nearly USD 60 million, earmarked for innovative-drug R&D, and CDMO R&D, and production-base construction.[1](https://bydrug.pharmcube.com/news/detail/6c2be0414dcbf8d92dd718ca0fd1754d) Some records render this round as "USD 388 million"; that figure is a currency mislabel: the round was RMB 388 million, which corresponds to roughly USD 58 to 60 million at April 2022 exchange rates, matching the trade-press and company figures.[1](https://bydrug.pharmcube.com/news/detail/6c2be0414dcbf8d92dd718ca0fd1754d) • [2](https://news.qq.com/rain/a/20220519A0846300)
The company's own newsroom states cumulative financing of over RMB 1.2 billion in the five years to 2025, and the registry profile records a later C3 round of nearly RMB 200 million directed at innovative-drug R&D and AI technology upgrades.[3](https://www.vcarepharmatech.com/news_detail/29.html) • [5](https://m.qcc.com/firm/1ec634273b2cf7a4ff4345833a2547be.html)
## Business and traction
Independent regulatory records back parts of the company's story. In May 2022 vicagrel capsules received NMPA clinical-trial clearance for mild acute ischemic stroke or transient ischemic attack, with a Phase II trial to begin imminently alongside the ongoing China Phase III.[2](https://news.qq.com/rain/a/20220519A0846300) In June 2025, according to the company, its first self-developed class-1 innovative drug, 维迈妥® (generic name 安瑞曲替尼, [Eratrectinib](https://www.edgepedia.org/eratrectinib), code VC004), a next-generation TRK inhibitor for adults and adolescents aged 12 and over with NTRK fusion solid tumors, won NMPA approval through priority review; the company describes it as the world's third next-generation TRK inhibitor.[3](https://www.vcarepharmatech.com/news_detail/29.html)
Company-claimed and registry-recorded distinctions include Nanjing cultivated-unicorn and gazelle (瞪羚) enterprise listings in 2022, provincial R&D platforms, and national recognitions as a 2024 specialized-and-new "little giant" (专精特新"小巨人") enterprise and a 2025 high-tech enterprise.[2](https://news.qq.com/rain/a/20220519A0846300) • [5](https://m.qcc.com/firm/1ec634273b2cf7a4ff4345833a2547be.html) In June 2026 the registry profile records that Vikeer licensed vicagrel to 云顶新耀 ([Everest Medicines](https://www.edgepedia.org/everest-medicines)) for development and commercialization in the Asia-Pacific region, with upfront and milestone payments.[5](https://m.qcc.com/firm/1ec634273b2cf7a4ff4345833a2547be.html)
## How it compares with Chinese CDMO peers
Vikeer is a small player against China's large listed CDMOs. [WuXi AppTec](https://www.edgepedia.org/wuxi-apptec) reported chemical CDMO revenue growth of 139% year on year in the first quarter of 2022, held 1,808 CDMO projects as of March 2022 (49 in Phase III, 42 commercial), and planned RMB 9 to 10 billion of capital expenditure in 2022, about 60% of it for chemical CDMO.[4](https://pdf.dfcfw.com/pdf/H3_AP202204271561920305_1.pdf) Vikeer's roughly ten internal programs and RMB 200 million research center are two orders of magnitude smaller on the pipeline and capex measures.[1](https://bydrug.pharmcube.com/news/detail/6c2be0414dcbf8d92dd718ca0fd1754d) • [4](https://pdf.dfcfw.com/pdf/H3_AP202204271561920305_1.pdf) Its stated differentiation is the combination of contract services with its own innovative-drug pipeline, a model in which CDMO cash flow supports proprietary drug development.[2](https://news.qq.com/rain/a/20220519A0846300)
## Recent developments
Several developments mark the move from clinical-stage to commercial-stage company. The entity was reorganized as a joint-stock company (股份有限公司).[3](https://www.vcarepharmatech.com/news_detail/29.html) Headcount grew from about 400 in 2022 to more than 900, with over 84% technical staff and more than 200 master's or PhD holders.[3](https://www.vcarepharmatech.com/news_detail/29.html) The company now describes itself as a commercial-stage, AI-enabled innovative biopharma, and the C3 round was directed partly at AI technology upgrades.[3](https://www.vcarepharmatech.com/news_detail/29.html) • [5](https://m.qcc.com/firm/1ec634273b2cf7a4ff4345833a2547be.html) The June 2025 NMPA approval of Eratrectinib and the 2026 vicagrel out-licensing to Everest Medicines are the two most consequential events in the record.[3](https://www.vcarepharmatech.com/news_detail/29.html) • [5](https://m.qcc.com/firm/1ec634273b2cf7a4ff4345833a2547be.html)
## References
1. [再传融资捷报！江苏威凯尔完成A2轮融资 (PharmCube/ByDrug)](https://bydrug.pharmcube.com/news/detail/6c2be0414dcbf8d92dd718ca0fd1754d)
2. [江苏威凯尔I类抗血栓新药维卡格雷胶囊获批缺血性脑卒中临床II期研究 (Tencent News)](https://news.qq.com/rain/a/20220519A0846300)
3. [威凯尔医药首款自研1类创新药维迈妥®（安瑞曲替尼）上市 (company site)](https://www.vcarepharmatech.com/news_detail/29.html)
4. [WuXi AppTec equity research report, April 2022](https://pdf.dfcfw.com/pdf/H3_AP202204271561920305_1.pdf)
5. [江苏威凯尔医药科技股份有限公司 (Qichacha registry profile)](https://m.qcc.com/firm/1ec634273b2cf7a4ff4345833a2547be.html)
---
*Topic: Encyclopedia › Society and history › Economics and business › Business and work › Business and work overview › Companies and corporations › Venture-backed startups and growth companies › Health, biotech, and medtech startups › Small-molecule and chemical drug developers*
*Initially written Sep 17, 2026 · Edited: Oct 11, 2026; Oct 15, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license